SOPHiA GENETICS Raises $110M to Meet Growing Clinical and Biopharma Demand for Data-Driven Medicine

Sophia Genetics

SOPHiA GENETICS Raises $110M to Meet Growing Clinical and Biopharma Demand for Data-Driven Medicine



SOPHiA GENETICS, global leader in Data-Driven Medicine, announced a $110M Series F round, led by aMoon, a leading health-tech & life sciences venture fund based in Israel, and Hitachi Ventures, a venture arm of Japanese Hitachi Group.Financial institutions including Credit Suisse and the Pictet group also joined the round alongside other new and existing investors. Balderton originally invested in SOPHiA GENETICS in 2017.

Having established the world’s largest Data-Driven Medicine community network through its universal and collaborative AI platform, SOPHiA GENETICS supports healthcare professionals by translating any complex medical data into valuable clinical insights.

Everyday SOPHiA provides 1000s of clinicians machine-learning tools to diagnose cancer and other diseases at over 10 times the speed and at a fraction of the cost as was possible just a few years ago. This is why innovation and investment matters. It is such a pleasure to be on the board.

James Wise, Partner, Balderton

The SOPHiA Platform is used by over 1000 healthcare institutions and has analysed 600,000 genomic profiles; up to 17,000 new profiles a month. Through continual learning and network effects, experts worldwide are empowered to act with confidence for better patient management.

SOPHiA has been establishing an impressive track record, truly acting as a disruptor in the healthcare landscape, with a rapid evolution directly impacting the extent of its decentralized approach. This new funding round will give a fresh impetus to the company’s performance and bring it to an even stronger future to achieve the biggest possible impact on patients and new targeted therapies

Troy Cox, Chairman of the Board of Directors of SOPHiA GENETICS

The new funding round will boost the company’s penetration in both the US and Asian markets. Proceeds will also be dedicated to increasing the platform multimodal capabilities and its adoption by healthcare institutions worldwide. Leveraging this momentum, SOPHiA GENETICS will be best positioned to power biopharma’s effort to optimise and accelerate the development of new targeted therapies.

Since inception, we knew that leveraging a wide range of data modalities powered by cutting-edge technologies was key to sustainably deliver better outcomes to the global healthcare community. Now, with this new funding round, we can embark on the next stage of our development and take our collaborative approach further, delivering intelligent medicine, together.

Jurgi Camblong, CEO and Founder at SOPHiA GENETICS

Read the full press release from SOPHiA here


Related content